Dong Chen1, Jiang Liu1, Hui-Ying Zhao1, Yi-Peng Chen1, Zun Xiang1, Xi Jin1. 1. Dong Chen, Hui-Ying Zhao, Department of Colorectal Surgery, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.
Abstract
AIM: To investigate the expression pattern of plasma long noncoding RNAs (lncRNAs) in Chrohn's disease (CD) patients. METHODS: Microarray screening and qRT-PCR verification of lncRNAs and mRNAs were performed in CD and control subjects, followed by hierarchy clustering, GO and KEGG pathway analyses. Significantly dysregulated lncRNAs were categorized into subgroups of antisense lncRNAs, enhancer lncRNAs and lincRNAs. To predict the regulatory effect of lncRNAs on mRNAs, a CNC network analysis was performed and cross linked with significantly changed lncRNAs. The overlapping lncRNAs were randomly selected and verified by qRT-PCR in a larger cohort. RESULTS: Initially, there were 1211 up-regulated and 777 down-regulated lncRNAs as well as 1020 up-regulated and 953 down-regulated mRNAs after microarray analysis; a heat map based on these results showed good categorization into the CD and control groups. GUSBP2 and AF113016 had the highest fold change of the up- and down-regulated lncRNAs, whereas TBC1D17 and CCL3L3 had the highest fold change of the up- and down-regulated mRNAs. Six (SNX1, CYFIP2, CD6, CMTM8, STAT4 and IGFBP7) of 10 mRNAs and 8 (NR_033913, NR_038218, NR_036512, NR_049759, NR_033951, NR_045408, NR_038377 and NR_039976) of 14 lncRNAs showed the same change trends on the microarray and qRT-PCR results with statistical significance. Based on the qRT-PCR verified mRNAs, 1358 potential lncRNAs with 2697 positive correlations and 2287 negative correlations were predicted by the CNC network. CONCLUSION: The plasma lncRNAs profiles provide preliminary data for the non-invasive diagnosis of CD and a resource for further specific lncRNA-mRNA pathway exploration.
AIM: To investigate the expression pattern of plasma long noncoding RNAs (lncRNAs) in Chrohn's disease (CD) patients. METHODS: Microarray screening and qRT-PCR verification of lncRNAs and mRNAs were performed in CD and control subjects, followed by hierarchy clustering, GO and KEGG pathway analyses. Significantly dysregulated lncRNAs were categorized into subgroups of antisense lncRNAs, enhancer lncRNAs and lincRNAs. To predict the regulatory effect of lncRNAs on mRNAs, a CNC network analysis was performed and cross linked with significantly changed lncRNAs. The overlapping lncRNAs were randomly selected and verified by qRT-PCR in a larger cohort. RESULTS: Initially, there were 1211 up-regulated and 777 down-regulated lncRNAs as well as 1020 up-regulated and 953 down-regulated mRNAs after microarray analysis; a heat map based on these results showed good categorization into the CD and control groups. GUSBP2 and AF113016 had the highest fold change of the up- and down-regulated lncRNAs, whereas TBC1D17 and CCL3L3 had the highest fold change of the up- and down-regulated mRNAs. Six (SNX1, CYFIP2, CD6, CMTM8, STAT4 and IGFBP7) of 10 mRNAs and 8 (NR_033913, NR_038218, NR_036512, NR_049759, NR_033951, NR_045408, NR_038377 and NR_039976) of 14 lncRNAs showed the same change trends on the microarray and qRT-PCR results with statistical significance. Based on the qRT-PCR verified mRNAs, 1358 potential lncRNAs with 2697 positive correlations and 2287 negative correlations were predicted by the CNC network. CONCLUSION: The plasma lncRNAs profiles provide preliminary data for the non-invasive diagnosis of CD and a resource for further specific lncRNA-mRNA pathway exploration.
Authors: Daniel C Baumgart; Charles N Bernstein; Zaigham Abbas; Jean F Colombel; Andrew S Day; Geert D'Haens; Iris Dotan; Khean L Goh; Toshifumi Hibi; Richard A Kozarek; Eamonn M M Quigley; Walter Reinisch; Bruce E Sands; Jose D Sollano; A Hillary Steinhart; Flávio Steinwurz; Morten H Vatn; Jesús K Yamamoto-Furusho Journal: Inflamm Bowel Dis Date: 2011-02 Impact factor: 5.325
Authors: Lindsay B McKenna; Jonathan Schug; Anastassios Vourekas; Jaime B McKenna; Nuria C Bramswig; Joshua R Friedman; Klaus H Kaestner Journal: Gastroenterology Date: 2010-07-24 Impact factor: 22.682
Authors: Aashiq H Mirza; Claus Hb Berthelsen; Stefan E Seemann; Xiaoyong Pan; Klaus S Frederiksen; Mogens Vilien; Jan Gorodkin; Flemming Pociot Journal: Genome Med Date: 2015-05-13 Impact factor: 11.117
Authors: Manuel B Braga-Neto; Joseph M Gaballa; Adebowale O Bamidele; Olga F Sarmento; Phyllis Svingen; Michelle Gonzalez; Guilherme Piovezani Ramos; Mary R Sagstetter; Sayed Obaidullah Aseem; Zhifu Sun; William A Faubion Journal: J Crohns Colitis Date: 2020-01-01 Impact factor: 9.071